According to new evidence provided on CV safety in T2DM patients, the use of both GLP1-RA and SGLT2 inhibitors is strongly recommended in the patients with T2DM with high or very-high CVr, regardless of the metabolic compensation (5, 11). Here, SLC5A2 is linked to type 2 diabetes mellitus.